Key Market Indicators
New Zealander sales of diabetes medicine are projected to soar to approximately $175 million by 2028, up from roughly $94 million in 2023. This represents a robust annual growth rate of 9.6%. Since 1998, the New Zealand market has experienced a significant year-on-year increase of 18.9%. In 2023, New Zealand was ranked eighth globally, with Slovakia slightly ahead at the same $94 million mark. Italy, Australia, and Croatia hold the second, third, and fourth spots, respectively. In terms of insulin imports, New Zealand is set to reach about $25 million by 2028, growing from $22 million in 2023. This marks an annual growth rate of 1.9%. Since 1994, the country's insulin demand has seen a steady rise of 3.3% annually. New Zealand's insulin exports are also on the rise, expected to hit close to $381,000 by 2028, up from around $340,000 in 2023. This indicates an average yearly growth rate of 1.7%. Since 1994, New Zealand's insulin supply has increased by 4.1% each year. In 2023, New Zealand ranked 29th globally in insulin exports, with Slovenia surpassing them with the same $340,000 figure. France, Italy, and China occupy the second, third, and fourth positions in this ranking.
